During recent years a variety of non-isotopic immunoassays have been introduced for therapeutic drug monitoring, for toxicological purposes, and for the detection of drug abuse. All involve covalently coupling the drug, or an analogue, to a non-isotopic label (such as an enzyme or f1uorophore) for use as the tracer, and to carrier protein for use as the immunogen to raise antisera. Immunogen and tracer preparation may seem relatively straightforward to those not actively involved. On occasion this is the case, but more commonly several products must be synthesised to attain success. Such difficulties are seldom apparent in the scientific literature where limitations of space usually preclude the reporting of all, but successful experiments. This is unfortunate since the central role often played by the synthetic chemist may be overlooked.
As an example of the typical problems that may be encountered it seemed of interest to summarise our experiences when raising antisera and preparing a label for use in a direct polarisation f1uoroimmunoassay (PFIA) for paracetamol. This presented a considerable challenge because of the small size (151 daltons) and simple molecular structure of the drug, which comprises only three functional groups; an acetamide, an aromatic phenyl ring, and a phenolic hydroxyl group (Fig. 1 ). An enzymoimmunoassay (EMIT,) (Syva Syntex Pharmaceuticals Ltd, Maidenhead, Berks, UK)
Correspondence: G Gallacher. 42 and a polarisation f1uoroimmunoassay (PFIA) (TDx, Abbott, Laboratories Ltd, Esher, Surrey, UK) for paracetamol are available, and although an evaluation of the enzymoimmunoassay has been publishedI the development of these immunoassays has not been described. This paper dicusses the investigations leading to the design and synthesis of an immunogen and fluorescent tracer which enabled the development of a successful PFIA for paracetamoI. Organic solutions were dried by stirring over anhydrous magnesium sulphate, followed by filtration. Where purification by tic is indicated, silica gel sheets 20 cmx20 cmxO·2 mm were used and the developing solvent is shown in brackets.
Materials and methods

Fluorescein
All assays were performed in 0·1 M sodium 2) The p-aminophenol hemisuccinide (21 mg, 0·1 mmol) was dissolved in a mixture of acetonitrile (2 mL) and water (0,20 mL). NHydroxysuccinamide (12 mg, O·} mmol) and EDC (20 mg, o·} mmol) were then added.
Formation of the activated ester was monitored as described above and, when complete, a (3X25 mL) the solution was acidified with 1 M hydrochloric acid (maintaining the temperature at O°C). and extracted with ethyl acetate (3X50 mL). The acid extracts were dried, and concentrated in vacuo to give the N-tbutoxycarbonyl aminocaprylic acid (1,52 g, yield 94%) as a colourless oil. A portion (259 mg. 1 mmol) was dissolved in acetonitrile (2 mL), cooled to O"C, and triethylamine (0,14 mL, 1 mmol) and pivaloylchloride (0·12 mL, 1 mmol) added. The reaction was stirred at O"C for 20 min, p-aminophenol (109 mg, 1 mmol) and triethylamine (0·14 mL) added, and the mixture stirred at O"C for 1 h. The reaction mixture was diluted with ethyl acetate (20 mL), washed with 1 Mhydrochloric acid (2X10 mL) and 1 M sodium bicarbonate (IX10 mL), dried, and concentrated in vacuo. The product (Rf: 0·33) was isolated by tIc (ethyl acetate:petroleum ether 3:2) to give the pure butoxycarbonyl-protected derivative (158 mg, yield 45%) as a colourless oil.
A portion (10 mg, 0·028 mmol) of this derivative was deprotected by stirring in trifluoroacetic acid (I mL) at room temperature for 1 h. Volatiles were then removed in vacuo to give the primary amine (7 mg, yield 100%) as a colourless oil, which was dissolved in methanol (1 ml.) and triethylamine (0·05 mL). FITC (10 mg, 0·026 mmol) was added, and the reactants stirred at room temperature for 16 h. The crude product was precipitated by addition of 1 M-ammonium acetate buffer (pH 4) (5 mL), filtered, and purified by tIc (ethyl acetate:methanol 9:1; Rf:0·4) to give the pure fluorescein-labelled paracetamol (Fig. 3) . The concentration of label in the methanol eluate was determined as described above. (FIG. 3) 2-t-Butoxycarbonyloxyimino-2-phenylace -tonitrile (BOC-ON) (1,55 g. 6·3 mmol) was added portionwise to a solution of 8-aminoca-prylic acid (I g, 6·3 mmol) in methanol (50 mL) and triethylamine (0·9 mL, 6·3 mmol). The mixture was stirred at room temperature for 16 h, concentrated in vacuo, and the residue suspended in aqueous 1 Msodium bicarbonate (25 mL) at O"C. After extraction with ethyl acetate solution of fluorescein thiocarbamyl ethylenediamine (45 mg, 0·1 mmol) in acetonitrile (1 mL) containing water (0,20 mL) and triethylamine (0·20 mL) was added. The mixture wasstirred at room temperature for 1 h, and the crude product precipitated by the addition of 1 M aqueous hydrochloric acid (5 mL). After filtration, a portion of the solid was purified by tic (chloroform:methanol 3:1, RfO·33). Elution with methanol gave a solution of the pure fluorescein label whose concentration was determined as described above.
background signal contributed by the antisera by means of control tubes containing no fluorophore-Iabelled drug. The measurements were made using a polarisation fluorimeter (Model 4000 SLM Instruments, Urbana IL 61801, USA). This is a 'T-format' instrument used as described" in a previous paper, except that the wavelength was set at 492 nm and the cuvette chamber modified to accept cylindrical cuvettes. This approach is based on the small signal given by a labelled hapten due to its rapid rate of Brownian motion, and the much larger signal that results when the tracer is bound by an antibody. The maximum range of the signal is from 0 to 0·5 P and, for convenience, the results are multiplied by 1000 and expressed as mP.
Inhibition curves were constructed using a stock solution of 1 gIL of the drug in assay buffer diluted, before use, to give 50, 100,500 and 1000 mglL working standards. These (10 !-LL) were vortex mixed with the label (0·5 ml, 30 nmol/L) and an appropriate dilution of antiserum (1 mL), incubated for 60 min at room temperature, and fluorescence polarisation measured as above.
Results
STUDIES WITH PARACETAMOL HEMISUCCINATE CONJUGATES
Fluorescein-labelled paracetamol hemisuccinate at a concentration of 10 nmoVL gave a small Paracetamol at concentrations of up to 1000 mglL (6·6 mmoVL) was not able to compete with the label for antibody binding sites. In contrast, paracetamol hemisuccinate produced a marked fall in fluorescence polarisation at levels as low as 50 mglL (Fig. 4) indicating that the antibodies raised against the paracetamol hemisuccinate-KLH immunogen recognised the drug-bridge, and required both for antibody binding. That the antibodies did not recognise paracetamol alone was confirmed by means of antiserum dilution curves using r 3 H]-paracetamol in which no antibody binding occured.
Furthermore, this derivative was a poor immunogen as evidenced by the low titres of antibodies produced in only one of three immunised sheep.
STUDIES WITH P-AMINOPHENOL HEMISUCCINIDE CONJUGATES
Antisera raised in three sheep against the immunogen prepared by coupling p-aminophenol hemisuccinide to KLH, were assessed using the label obtained by coupling the same derivative to fluorescein-thiocarbamyl ethylenediamine. All three sheep produced antibodies as evidenced by an increase in the fluorescence polarisation signal of the labelled drug from 40 mP in buffer to more than 20() mP. The titres at which the antisera could be employed were also satisfactory being I:600, I:30(), and I:30()O for Sheep 33, 34, and 35, respectively (Fig. 5) . However, as shown in Fig. 6 , using an antiserum from Sheep 35 at a dilution of I:3()OO, competition by paracetamol with the label for antibody binding sites was poor at concentrations relevant to clinical practice, indicating a degree of preferential binding of this label.
STUDIES WITH FLUORESCEIN LABELLED P-CAPRYLAMI DOPHENOL
A label incorporating a heterogeneous bridge . was synthesised (Fig. 3) to reduce preferential binding. This label was bound by the p-aminophenol hemisuccinide antisera, again increasing the polarisation signal from 40 mP to more than 200 mP. Titres were similar to those obtained for the previous label containing the homogeneous bridge. . The new label exhibited considerably superior displacement by paracetamol, giving a sensitive assay. This is shown in Fig. 6 , using an antiserum from Sheep 35 at a dilution of 1:4800 and, in this case, only 5 ul, of each standard solution.
Discussion
The development of a PFIA for paracetamol . was undertaken as part of a programme to establish fluoroimmunoassays for a wide range of drugs. The key reactant in all such assays is the antiserum since, in large part, it determines the specificity achieved. This, in turn, depends on the chemistry employed for the covalent attachment of the drug, to the carrier protein in the immunogen. Antisera raised against the paracetamol hemisuccinate-KLH immunogen did not bind paracetamol, presumably because this coupling method destroyed one of the three functional groups summarised earlier. Transformation of the important, polar, ionisable, phenolic hydroxyl into an apolar ester (Fig. 1 ) altered the molecular structure to the extent that the antibodies recognised the drug and its derivative as entirely different entities.
Clearly a derivative of paracetamol capable of being coupled to protein, but with minimal structural alteration was required. PAminophenol hemisuccinide (Fig. 2) is an analogue which fulfillsthese criteria. The acetamide methyl is extended by an alkyl bridge of similar steric and electronic nature, terminating with the requisite carboxylic acid. Antisera raised against this derivative did indeed recognise paracetamol, but preferentially bound the fluorescent label prepared from the same derivative, resulting in an assay of poor sensitivity.
Preferential binding of the label is not uncommon and, again, organic chemistry provides the solution. The immunogen and label (Fig. 2) both contain the amide used to effect coupling, a structural feature not found in paracetamol. The antisera probably interact with this feature by hydrogen binding. Therefore, a label was synthesised (Fig. 3 ) in which this amide was replaced by a long hydrophobic alkyl chain. As expected, the new label exhibited considerably superior displacement by paracetamol (Fig. 6 ). This combination of antiserum and label gave a PFiA for paracetamol, in buffer, at the concentrations of interest for toxicological investigations. The development of a PFIA for the measurement of paracetamol in serum, using these reagents, is described in the following paper.
The design and synthesis of a suitable paracetamol immunogen and label was greatly facilitated by the active involvement of a synthetic chemistry group in the development of this assay.
